retrospect
analyz
infecti
complic
tandem
highdos
chemotherapi
autolog
stem
cell
transplant
hdctautosct
children
adolesc
highrisk
recurr
solid
tumor
total
patient
underw
first
hdct
autosct
octob
septemb
proceed
second
hdctautosct
total
hdctautosct
earli
transplant
period
hdctautosct
begin
hdct
day
posttranspl
bacteremia
urinari
tract
infect
uti
respiratori
viru
infect
varicella
zoster
viru
vzv
reactiv
occur
hdctautosct
respect
earli
transplant
period
second
hdctautosct
infecti
complic
similar
first
hdctautosct
late
transplant
period
hdct
autosct
day
year
posttranspl
bacteremia
uti
vzv
reactiv
occur
patient
respect
infecti
complic
late
transplant
period
occur
first
month
posttranspl
invas
fungal
infect
studi
period
six
patient
die
infecti
complic
bacteri
sepsi
respiratori
viru
infect
studi
suggest
infecti
complic
similar
follow
second
first
hdctautosct
children
highdos
chemotherapi
autolog
stem
cell
transplant
hdctautosct
improv
outcom
patient
highrisk
solid
tumor
infecti
complic
hdctautosct
major
caus
associ
treatmentrel
morbid
mortal
despit
advanc
infect
prophylaxi
treatment
hdctautosct
mani
clinic
problem
includ
emerg
multidrugresist
mdr
bacteria
risk
clostridium
difficil
infect
high
incid
bloodstream
infect
still
requir
research
recent
increas
number
studi
use
tandem
hdctautosct
find
suggest
dose
intensif
might
improv
outcom
patient
highrisk
recurr
tumor
howev
number
cell
session
tandem
hdctautosct
could
lower
singl
hdctautosct
half
collect
stem
cell
infus
hdctautosct
session
addit
second
hdctautosct
could
requir
longer
time
hematolog
recoveri
first
hdctautosct
even
similar
number
cell
infus
find
suggest
infecti
complic
might
frequent
sever
second
hdct
autosct
first
studi
address
infecti
complic
tandem
hdctautosct
limit
accordingli
investig
infecti
complic
tandem
hdctautosct
studi
review
approv
institut
review
board
samsung
medic
center
inform
consent
waiv
board
patient
recordsinform
anonym
deidentifi
prior
analysi
retrospect
review
medic
record
children
adolesc
highrisk
recurr
solid
tumor
underw
first
hdctautosct
octob
septemb
samsung
medic
center
period
octob
decemb
period
januari
septemb
defin
earli
late
studi
period
respect
period
begin
hdct
day
posttranspl
period
day
year
posttranspl
day
treatmentrel
mortal
tumor
relapseprogress
death
whichev
occur
first
defin
earli
late
transplant
period
respect
fever
defin
singl
axillari
temperatur
bacteremia
defin
isol
bacteri
pathogen
least
one
set
blood
cultur
one
aerob
one
anaerob
drawn
patient
coagulaseneg
staphylococci
corynebacteria
isol
least
two
set
blood
cultur
antibiogram
requir
septic
shock
defin
bacteremia
hypotens
use
inotrop
agent
urinari
tract
infect
uti
defin
urinari
symptom
andor
fever
hospit
record
posit
urin
cultur
posit
urin
cultur
defin
growth
colonyform
unitml
singl
organ
midstream
bag
urin
specimen
clostridium
difficil
infect
cdi
requir
presenc
diarrhea
defin
unform
stool
hour
radiograph
evid
ileu
toxic
megacolon
posit
stool
test
result
toxigen
clostridium
difficil
toxin
colonoscop
histopatholog
find
demonstr
pseudomembran
coliti
gramneg
isol
exhibit
resist
least
two
antibiot
use
empir
therapi
third
fourthgener
cephalosporin
carbapenem
piperacillintazobactam
defin
mdr
novemb
patient
fever
respiratori
symptom
chest
radiolog
abnorm
test
seeplex
multiplex
polymeras
chain
reaction
assay
seegen
inc
seoul
korea
respiratori
virus
rv
rhinoviru
rhv
respiratori
syncyti
viru
rsv
coronaviru
cov
parainfluenza
viru
piv
adenoviru
adv
influenza
viru
iv
rv
categor
group
accord
symptomatolog
clinic
outcom
lowrisk
rv
group
includ
rhv
cov
highrisk
rv
group
includ
rsv
piv
adv
iv
cytomegaloviru
cmv
diseas
diagnos
accord
publish
recommend
invas
fungal
infect
ifi
defin
criteria
set
european
organ
research
treatment
cancerinvas
fungal
infect
cooper
group
cefepim
use
firstlin
antibacteri
agent
teicoplanin
amikacin
ad
secondlin
agent
fever
persist
three
day
cefepim
fever
recur
despit
three
day
cefepim
treatment
antibiot
chang
teicoplanin
imipenem
year
age
meropenem
year
age
thirdlin
agent
patient
persist
neutropen
fever
addit
three
day
recurr
fever
treatment
secondlin
antibiot
three
day
june
onward
chang
antibiot
strategi
cefepim
firstlin
agent
teicoplanin
cefepim
use
secondlin
therapi
teicoplanin
meropenem
use
thirdlin
agent
octob
april
antifung
agent
use
prophylact
empir
antifung
agent
use
patient
howev
patient
receiv
antifung
prophylaxi
fluconazol
itraconazol
micafungin
may
antibiot
includ
antifung
agent
discontinu
three
consecut
day
signific
fever
evid
document
clinic
suspect
infect
absolut
neutrophil
count
exceed
l
except
prophylact
trimethoprimsulfamethoxazol
pneumocysti
jiroveci
prophylact
acyclovir
day
day
engraft
administ
prevent
vzv
reactiv
octob
june
use
sinc
juli
minim
drug
toxic
hdct
analyz
associ
incid
infecti
complic
potenti
clinic
laboratori
risk
factor
chisquar
test
fisher
exact
test
use
binari
variabl
mannwhitney
u
test
kruskalw
test
use
continu
variabl
multivari
analysi
perform
use
linear
regress
analysi
binari
logist
regress
test
examin
factor
associ
fever
durat
bacteremia
valu
statist
signific
accept
level
p
total
patient
male
femal
underw
first
hdctautosct
proceed
second
hdctautosct
total
hdctautosct
howev
remain
patient
could
proceed
second
hdctautosct
due
tumor
progress
n
offtreat
n
treatmentrel
mortal
n
followup
loss
n
subsequ
allogen
transplant
n
parent
refus
n
transplant
characterist
present
tabl
common
diagnosi
neuroblastoma
follow
brain
tumor
common
tandem
hdct
regimen
cec
carboplatin
etoposid
cyclophosphamid
follow
mibgtm
imetaiodobenzylguanidinetreat
thiotepa
melphalan
neuroblastoma
cte
carboplatin
thiotepa
etoposid
follow
cym
cyclophosphamid
melphalan
brain
tumor
fever
occur
earli
transplant
period
hdctautosct
median
durat
day
rang
multivari
analysi
inclus
total
bodi
irradi
tbi
andor
thiotepa
hdct
regimen
frequent
caus
sever
mucos
associ
longer
durat
fever
otherwis
differ
fever
durat
respect
variou
clinic
factor
tabl
interestingli
cell
number
affect
fever
durat
despit
differ
time
neutrophil
recoveri
accord
cell
number
total
episod
bacteri
infect
first
hdctautosct
second
hdctautosct
document
earli
transplant
period
hdctautosct
infect
includ
episod
bacteremia
episod
uti
episod
cdi
episod
bacteremia
caus
gramneg
organ
gramposit
organ
total
septic
shock
episod
occur
caus
gramneg
bacteremia
gramposit
bacteremia
three
patient
die
bacteri
sepsi
earli
transplant
period
hdctautosct
uti
caus
gramneg
bacteria
tabl
show
multivari
analysi
risk
factor
bacteremia
earli
transplant
period
hdctautosct
inclus
tbi
andor
thiotepa
hdct
regimen
lower
number
cell
kg
associ
frequent
gramposit
bacteremia
older
age
month
age
associ
frequent
gramneg
bacteremia
fig
incid
lrti
higher
highrisk
rv
group
lowrisk
rv
group
versu
p
fig
two
patient
die
rsv
adv
pneumonia
vzv
reactiv
occur
hdctautosct
includ
local
zoster
dissemin
zoster
without
viscer
involv
varicella
cmv
diseas
develop
patient
includ
retin
enterocol
may
patient
screen
presenc
rv
infect
hdct
autosct
n
rvneg
case
proceed
hdctautosct
howev
rvposit
patient
without
respiratori
symptom
proceed
hdctautosct
rv
disappear
wait
period
eight
experienc
clinic
respiratori
diseas
lrti
uri
hdctautosct
without
mortal
remain
patient
rvneg
prior
hdctautosct
rv
infect
develop
patient
experienc
clinic
respiratori
diseas
lrti
uri
antifung
agent
administ
prophylact
empir
hdctautosct
respect
case
proven
probabl
ifi
differ
transplant
characterist
first
second
hdct
autosct
except
higher
use
tbicontain
regimen
delay
platelet
recoveri
second
hdctautosct
tabl
incid
fever
proport
patient
use
secondlin
antibiot
higher
first
hdctautosct
second
hdct
fever
durat
also
longer
first
hdct
borderlin
signific
otherwis
signific
differ
infect
paramet
first
second
hdct
autosct
total
gramposit
gramneg
bacteria
isol
earli
late
studi
period
hdctautosct
common
mdr
gramneg
bacteria
extendedspectrumbetalactamas
esbl
produc
escherichia
coli
incid
chang
earli
studi
period
late
studi
period
death
bacteri
sepsi
earli
late
studi
period
caus
mdr
bacteria
stenotrophomona
maltophilia
n
carbapenemresist
acinetobact
baumannii
n
esblproduc
escherichia
coli
n
hdctautosct
c
highrisk
rv
group
higher
incid
lrti
lowrisk
rv
group
versu
p
studi
address
infecti
complic
associ
tandem
hdctautosct
children
adolesc
limit
studi
evalu
infecti
complic
patient
highrisk
solid
tumor
underw
tandem
hdctautosct
period
singl
institu
best
knowledg
largest
cohort
children
adolesc
underw
tandem
hdctautosct
gener
frequenc
sever
infecti
complic
cohort
similar
cohort
children
adolesc
st
jude
children
research
hospit
sjcrh
underw
singl
hdctautosct
initi
hypothes
infecti
complic
might
frequent
sever
second
hdctautosct
first
hdctautosct
contrast
found
episod
fever
frequent
proport
case
use
secondlin
antibiot
higher
first
hdctautosct
second
otherwis
differ
infect
paramet
first
second
hdctautosct
multivari
analysi
risk
factor
infecti
complic
tandem
hdctautosct
inclus
tbi
andor
thiotepa
frequent
caus
sever
mucos
signific
highrisk
factor
howev
second
hdctautosct
compar
first
hdctautosct
signific
factor
collect
find
suggest
second
hdctautosct
increas
sever
infecti
complic
compar
first
sever
infecti
complic
tandem
hdct
autosct
might
associ
hdct
regimen
rather
number
hdct
studi
overal
incid
bacteremia
earli
transplant
period
hdctautosct
lower
result
adult
studi
similar
incid
overal
bacteremia
seen
day
posttranspl
sjcrh
cohort
incid
bacteremia
might
accept
consid
natur
treatment
usual
prognosi
tumor
includ
studi
howev
mdr
bacteremia
might
signific
clinic
problem
studi
incid
mdr
bacteria
particularli
esblproduc
escherichia
coli
appear
increas
time
four
patient
die
mdr
bacteri
infect
find
suggest
infect
mdr
bacteria
might
substanti
clinic
problem
hdctautosct
futur
therefor
care
consider
use
antibiot
need
reduc
emerg
mdr
bacteria
current
guidelin
pediatr
patient
undergo
hdctautosct
anticip
neutropenia
day
recommend
administr
fluconazol
start
hdct
engraft
case
ifi
sjcrh
studi
use
fluconazol
day
posttranspl
studi
case
receiv
prophylact
empir
antifung
prophylaxi
ifi
occur
find
suggest
incid
ifi
children
solid
tumor
might
lower
incid
report
adult
hematolog
malign
studi
antifung
agent
use
hdctautosct
ifi
collect
find
suggest
need
evalu
whether
antifung
prophylaxi
need
hdctautosct
children
solid
tumor
patient
rv
infect
hdctautosct
usual
postpon
rv
infect
disappear
howev
patient
rv
infect
might
persist
long
time
without
symptom
seen
studi
signific
delay
hdctautosct
viral
clear
might
increas
risk
tumor
progress
clinician
might
determin
start
hdctautosct
patient
studi
rvposit
patient
without
respiratori
symptom
proceed
hdctautosct
rv
disappear
wait
period
eight
experienc
clinic
respiratori
infect
includ
lrti
howev
mortal
studi
show
incid
lrti
rel
low
lowrisk
rv
infect
case
mortal
taken
togeth
find
suggest
patient
lowrisk
rv
infect
prior
hdctautosct
could
proceed
hdctautosct
rel
lowrisk
sever
respiratori
infect
risk
tumor
progress
high
howev
patient
highrisk
rv
infect
care
consider
need
determin
start
hdctautosct
vzv
prophylaxi
controversi
hdctautosct
contrast
allogen
sct
although
patient
studi
receiv
vzv
prophylaxi
order
avoid
possibl
overlap
drug
toxic
hdct
incid
vzv
reactiv
rel
low
compar
previou
studi
howev
patient
experienc
vzv
reactiv
present
studi
seroposit
vzv
prior
hdct
autosct
therefor
vzv
prophylaxi
might
need
children
solid
tumor
seroposit
prior
hdctautosct
studi
need
infecti
complic
rv
infect
late
transplant
period
develop
patient
usual
remov
central
venou
cathet
month
second
hdctautosct
due
possibl
earli
relapseprogress
howev
patient
experienc
bacteremia
late
transplant
period
indwel
central
cathet
time
infect
isol
organ
gramposit
bacteria
find
suggest
earlier
remov
central
venou
cathet
could
reduc
risk
bacteremia
late
transplant
period
hdctautosct
addit
infecti
complic
late
transplant
period
occur
first
month
second
hdctautosct
therefor
care
immun
surveil
continu
least
month
posttranspl
summari
studi
suggest
incid
infecti
complic
retrospect
cohort
underw
tandem
hdctautosct
lower
seen
previou
report
adult
similar
report
childhood
cohort
underw
singl
hdctautosct
addit
incid
sever
infecti
complic
second
hdctautosct
higher
first
hdctautosct
howev
studi
retrospect
studi
divers
diseas
treatment
limit
abil
draw
solid
conclus
studi
need
reduc
risk
infecti
complic
tandem
hdctautosct
children
highrisk
recurr
solid
tumor
conceptu
kw
formal
analysi
ybc
